Display Settings:

Format

Send to:

Choose Destination
BMC Neurol. 2009 Jun 12;9 Suppl 1:S1. doi: 10.1186/1471-2377-9-S1-S1.

ADDME--Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective.

Author information

  • 1Apredica, 313 Pleasant Street, Watertown, MA 02472, USA. Katya@Apredica.com

Abstract

The advent of early absorption, distribution, metabolism, excretion, and toxicity (ADMET) screening has increased the attrition rate of weak drug candidates early in the drug-discovery process, and decreased the proportion of compounds failing in clinical trials for ADMET reasons. This paper reviews the history of ADMET screening and its place in pharmaceutical development, and central nervous system drug discovery in particular. Assays that have been developed in response to specific needs and improvements in technology that result in higher throughput and greater accuracy of prediction of human mechanisms of absorption and toxicity are discussed. The paper concludes with the authors' forecast of new models that will better predict human efficacy and toxicity.

PMID:
19534730
[PubMed - indexed for MEDLINE]
PMCID:
PMC2697629
Free PMC Article

Images from this publication.See all images (5)Free text

Figure 2
Figure 3
Figure 4
Figure 5
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk